

# Assessing agonist efficacy in an uncertain Em world



**David Roche<sup>1</sup>, Debora Gil<sup>2</sup>, Jesús Giraldo<sup>1</sup>**


<sup>1</sup>Laboratory of Systems Pharmacology and Bioinformatics, Institut de Neurociències and Unitat de Bioestadística,

Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain

<sup>2</sup>CVC, Centre de Visió per Computador, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain



## The operational model of agonism



$E_m \rightarrow$  Maximum effect of the system  
 $K_E \rightarrow$  Intrinsic efficacy

$$E = \frac{E_m \tau^n [A]^n}{(K_A + [A])^n + \tau^n [A]^n}$$

$$\tau = \frac{[R_0]}{K_E}$$

Operational Efficacy

$$[R_0] = [R] + [AR]$$

Asymptote Parameter

$$\alpha = \lim_{[A] \rightarrow \infty} E$$

$$\alpha = \frac{E_m \tau^n}{1 + \tau^n}$$




Location Parameter

$$[A_{50}] = [A]_{E=\frac{\alpha}{2}}$$

$$[A_{50}] = \frac{K_A}{\left(\frac{1}{2 + \tau^n}\right)^{\frac{1}{n}} - 1}$$

## Single or multiple Em for the same receptor?

Theoretical ("true") parameter values:  $Em=8000$ ,  $n=1$ ,  $\log(K_A)=-6$ ,  $\tau_1=1$ ,  $\tau_2=5$ ,  $\tau_3=100$



The operational model of agonism can find the "true" Em of the system

$\alpha > Em$  can be obtained from strong agonists or positive allosteric modulators



## Hypothesis and Proposal

Strong agonists and positive allosteric modulators can produce top values greater than Em estimated from full agonists


Either the estimated Em is not a true Em or there are multiple Em

Different Em values can arise from different active receptor conformations. An extension of the operational model of agonism is needed

## Methods. Differential Evolution (DE): An alternative technique for curve fitting



- DE is a very simple population-based, stochastic function minimizer
- DE is very powerful for solving real-valued, noisy, change over time, multimodal, nonlinear and non-differentiable functions
- DE is suitable for particular pharmacologic cases where many parameters are included in the equations as, for instance, allosterism



## References and Acknowledgements

(1) Black JW and Leff P (1983) Proc. R. Soc. Lond.B 220:141-162

(2) Leff P et al. (1990) J Pharmacol Methods 23(3):225-37

Acknowledgements. Spanish Ministerio de Ciencia e Innovación (SAF2010-19257)